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Pathogenesis of abdominal aortic
aneurysms: Possible role of differential
production of proteoglycans by smooth
muscle cells
James Melrose, PhD, John Whitelock, PhD, Qian Xu, BSc, and Peter Ghosh,
DSc, New South Wales, Australia
Purpose: In vivo and in vitro observations strongly suggest that marked differences exist
in the phenotype, growth, and matrix-producing capabilities of distinct smooth muscle
cell subpopulations. An earlier study from our laboratory showed differences in matrix
metalloproteinase expression patterns in cultures of medial smooth muscle cells from tis-
sue affected by abdominal aortic aneurysm (AAA) or atherosclerotic occlusive disease
and from normal arterial tissue. In this study we were interested in ascertaining whether
smooth muscle cells from the same sample groups also synthesized different proteogly-
can profiles that correlated with vascular disease.
Methods: Proteoglycans from smooth muscle cell monolayer cultures from tissue affected
by AAA or atherosclerotic occlusive disease and from normal arterial tissue were exam-
ined by means of immunoblotting and affinity-blotting composite agarose polyacryl-
amide gel electrophoresis (CAPAGE) and sodium dodecyl sulphate PAGE. Enzyme-
linked immunosorbent assay (ELISA) was used to quantitate perlecan levels in smooth
muscle cell monolayer media samples.
Results: Versican, perlecan, and biglycan levels were significantly elevated in AAA smooth
muscle cell cultures. Two populations of smooth muscle cell versican were identified by
means of CAPAGE-immunoblotting and by means of a novel affinity-blotting technique
with biotinylated hyaluronan. A small keratan sulfate–substituted proteoglycan was pre-
sent in similar levels in all smooth muscle cell cultures. This proteoglycan had a free core
protein of about 55 kd after keratanase digestion and had a relatively high charge-to-
mass ratio, as was evident from its electrophoretic mobility in CAPAGE; this proteogly-
can was tentatively identified as keratocan. Immunoblotting with monoclonal antibod-
ies 3-G-10 (anti-D heparan sulfate, heparan sulfate stubs generated by heparitinase treat-
ment) and 10-E-4 (anti–native heparan sulfate chains) helped identify several smooth
muscle cell heparan sulfate–substituted proteoglycans. Elevated levels of intact and
processed perlecan core protein were identified in AAA cultures by means of
immunoblotting with a monoclonal antibody to perlecan core protein (A76). ELISA
measurements confirmed that perlecan levels were significantly higher in AAA smooth
muscle cell cultures compared with the normal arterial tissue and tissue affected by ath-
erosclerotic occlusive disease.
Conclusions: Because heparan sulfate proteoglycans can bind growth factors, their ele-
vated synthesis by AAA smooth muscle cells in combination with an increased expres-
sion of matrix metalloproteinases may at least partly explain the differential proliferative
capacity of the AAA smooth muscle cells examined and may govern the pattern of abnor-
mal cellular proliferation and matrix protein synthesis observed in the pathogenesis of
vascular disease. (J Vasc Surg 1998;28:676-86.)
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Proteoglycans are minor components of the nor-
mal arterial wall, but their accumulation in intimal
lesions of blood vessels is a typical event in the early
phases of atherosclerotic occlusive disease and
abdominal aortic aneurysm (AAA) development.1-3
Arterial proteoglycans can interact with a number 
of extracellular matrix macromolecules that influ-
ence arterial viscoelasticity, permeability, lipid accu-
mulation, hemostasis, and thrombosis.1,3-5 Smooth 
muscle cells synthesize several heparan sulfate–
substituted,6-10 chondroitin sulfate–substituted,11-13
and dermatan sulfate–substituted2,14 proteoglycans.
These include the transmembrane syndecan family,7
interstitial-extracellular matrix heparan sulfate–rich
and chondroitin sulfate–rich proteoglycans perlecan
and versican,10,12,14 and the dermatan sulfate–rich
proteoglycan biglycan.14
The heparan sulfate proteoglycans (syndecan, per-
lecan) can act as low-affinity receptors for basic
fibroblast growth factor (FGF), which may regulate
the availability of this growth factor in the vessel
wall.15-18 Biglycan is a small, leucine-rich repeat pro-
teoglycan that contains two dermatan sulfate chains.19
It has a cell surface and pericellular localization, but its
exact function in the vessel wall is unknown. Biglycan
can bind and thus control the bioavailability of trans-
forming growth factor b and inhibit fibrillogenesis of
type I collagen (the most abundant collagen in the
vessel wall) in vitro.20,21 Thus it may control matrix
accumulation and organization, processes relevant to
the pathobiologic process of AAA and atherosclerotic
occlusive disease. Versican has been shown to accu-
mulate in intimal lesions of atherosclerotic vessels and
is implicated in the entrapment of low-density
lipoprotein in the arterial wall during atherogene-
sis.4,13 Although arterial proteoglycans are quantita-
tively minor structural components of the vessel wall,
they may influence its physicochemical properties.
This study was undertaken to compare proteoglycans
synthesized by smooth muscle cells of persons with
AAA or atherosclerotic occlusive disease and of nor-
mal media to determine whether variations in these
proteoglycans can be correlated with disease process-
es in the vessel wall.
METHODS
Materials. Materials were obtained from the
sources indicated in an earlier publication, except
where noted.22 Dulbecco’s modified Eagles medium
(DMEM; high glucose and pyruvate containing L-glu-
tamine) was purchased from Gibco BRL, Sydney,
Australia. The anti–native heparan sulfate (clone F48-
10-E-4),8 anti- D heparan sulfate (clone 3-G-10),8
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anti–keratan sulfate (clone 5-D-4),23 monoclonal anti-
bodies, and heparitinase (Flavobacterium heparinum)
were purchased from the Seikagaku Corp., Tokyo,
Japan. Antibodies LF-51 and LF-9924 were kindly
provided by Dr. L. Fisher, National Institute of Dental
Research, National Institutes of Health, Bethesda,
Md. Novex see-blue prestained protein standards were
run as size markers: myosin (250 kd), bovine serum
albumin (BSA; 98 kd), and glutamic dehydrogenase
(64 kd), alcohol dehydrogenase (50 kd), and carbonic
anhydrase (36 kd). The novex broad range protein
standards also used were myosin (200 kd), b -galac-
tosidase (116.3 kd), phosphorylase b (97.4 kd), BSA
(66.3 kd), glutamic dehydrogenase (55.4 kd), lactate
dehydrogenase (36.5 kd), carbonic anhydrase (31 kd),
and soybean trypsin inhibitor (21.5 kd).
Patients and tissue specimens. All tissue har-
vesting and laboratory procedures were approved by
the medical research ethics committee of the Royal
North Shore Hospital (ethics no. 9501-02M).
Specimens were obtained with informed consent.
Specimens of AAA (n = 6) were obtained from the
anterior infrarenal aortic wall at the time of operative
AAA repair (median age 66 years, range 48 to 83
years). Specimens of atherosclerotic occlusive disease
(n = 5) were obtained from the anterior infrarenal
aortic wall from patients undergoing operative
bypass for aortic occlusive disease (median age, 54
years; range, 45 to 63 years). Normal arterial tissue
(n = 5) macroscopically free of atheroma was
obtained from inferior mesenteric arteries within 3
cm of their insertion in the infrarenal aorta from
patients undergoing left hemicolectomy for rectal
cancer (median age, 57 years; range, 46 to 85 years).
All patients in the study were men.
Culture of smooth muscle cells. Surgical speci-
mens were transported in ice cold, sterile phosphate-
buffered saline solution to the laboratory, where the
medial arterial tissues were dissected free of intima
and adventitia in a laminar flow hood and diced into
1 · 1 mm3 cubes. Medial explants were cultured at
37° C in DMEM supplemented with 10% fetal calf
serum under an atmosphere of 5% CO2 in air and
were maintained at 95% humidity. The smooth mus-
cle cells that grew out of the explants were established
as monolayer cultures. Once confluent, the smooth
muscle cell monolayers were trypsinized and subpas-
saged. Smooth muscle cells from the fifth passage
were seeded at a density of 2.5 · 105 per 25 cm2 in
canted neck flasks in 5 ml of DMEM/10% fetal calf
serum medium. The smooth muscle cells were fed
every 48 hours, and the media were collected for
examination of their constituent proteoglycans.
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Confirmation of smooth muscle cell phenotype
by means of immunofluorescence microscopy. To
confirm the smooth muscle cell phenotype, monolay-
er cells in their fifth passage were allowed to attach to
glass coverslips for 3 days. They were then fixed in ice
cold acetone, air dried, and incubated for 1 hour at
room temperature with a 1/500 dilution of
anti–smooth muscle cell a -actin monoclonal anti-
body. The coverslips were then washed in phosphate-
buffered saline solution, and a 1/200 dilution of goat
anti-mouse IgG fluorescein isothiocyanate–conjugat-
ed secondary antibody was added for 30 minutes at
room temperature. The samples were washed again,
and the coverslips were mounted on microscope slides
and examined under epifluorescent illumination with
a Leica MPS-60 fluorescent microscope.
Purification of media proteoglycans from
monolayer culture of smooth muscle cells. Media
samples were precipitated overnight at 4° C with 3
volumes of absolute ethanol, collected by means of
centrifugation (800g for 10 minutes), redissolved
overnight in 8 mol/L urea, 10 mmol/L 2-amino-2-
(hydroxymethyl)-1, 3-propanediol (TRIS) acetate at
pH 6.3, and 0.15 mol/L NaCl, and applied to a col-
umn of diethylaminoethyl (DEAE) sepharose
CL6B. The column was washed with 4 bed volumes
of starting buffer to remove nonbound material, and
the bound proteoglycans were eluted with 4 mol/L
GuHCl, 50 mmol/L TRIS HCl at pH 7, dialyzed
against distilled water, and freeze dried.
Composite polyacrylamide agarose gel elec-
trophoresis of smooth muscle cell proteoglycans.
Slab gels (0.15 · 14 · 14 cm) of 0.6% agarose 1.2%
acrylamide were cast in 10 mmol/L TRIS acetate
pH 6.3 buffer containing 0.25 mmol/L sodium sul-
fate.22 Proteoglycan samples (1.0 m g hexuronic
acid/10 m L per well) were subjected to elec-
trophoresis in 10 mmol/L TRIS acetate running
buffer at pH 6.3 containing 1 mmol/L sodium sul-
fate at 150 volts for 2 hours.22 The gels were either
stained for 30 minutes in a solution of 0.02%
weight/vol toluidine blue in 0.1 mol/L acetic acid
or electroblotted to nitrocellulose membranes.
Immunoblotting and affinity blotting.
Composite agarose polyacrylamide gel electrophore-
sis (CAPAGE) gels were blotted to nitrocellulose
membranes in 25 mmol/L TRIS, 192 mmol/L
glycine transfer buffer at pH 8.3 in a Bio-rad trans-
blot semidry transfer cell at 5.5 mA/cm2 constant
current for 30 minutes.22 The blots were blocked 3
hours in either 0.1% vol/vol polyoxyethylene (20)-
sorbitan monolaurate (Tween 20) in 20 mmol/L
TRIS HCl at pH 7.2 and 500 mmol/L NaCl (Tris-
buffered saline solution [TBS]; biotinylated hyaluro-
nan [bHA] affinity blots)22 or 5% weight/vol low-fat
skim milk in 50 mmol/L TRIS HCl at pH 7.4, 0.15
mol/L NaCl and 0.02% weight/vol NaN3
(immunoblots). Selected blots (LF-51, LF-99) were
predigested overnight with chondroitinase ABC
(0.025 units/mL) in 5% weight/vol skim milk in 50
mmol/L TRIS HCl at pH 7.2 containing 0.15
mol/L NaCl, 0.03 mol/L sodium acetate, and
0.02% weight/vol sodium azide. This digestion step
also acted as a blocking step for the membrane. The
primary reagents, that is, antibodies (5-D-4, A76) or
bHA22 (Table I) were applied in either TBS 0.05%
Tween 20 (TBS-Tween) or 20 mmol/L TRIS HCl at
pH 7.4 containing 0.1 mol/L NaCl (3-G-10, 10-E-
4, LF-51, LF-99) and allowed to bind for 1 hour. The
blots were then washed in the same buffer and incu-
bated with an appropriate alkaline phosphatase–
conjugated secondary antibody (1/1000 dilution) or
avidin-labeled alkaline phosphatase conjugate (0.5
m g/mL) for 1 hour. After washing, a solution of
nitro blue tetrazolium/bromo-choroindolyl phos-
phate in alkaline phosphatase assay buffer was added
for the visualization step. Selected blots were sub-
jected to densitometric scanning with ScanAnalysis
software (Biosoft, Cambridge, United Kingdom,
Ferguson, Mo) to semiquantitate particular proteo-
glycan bands.
Perlecan enzyme-linked immunosorbent assay.
Tenfold serial dilutions of affinity-purified human
umbilical artery endothelial cell (HUAEC) perlecan
(1 m g to 0.01 pg/well) and tenfold concentrated
purified smooth muscle cell media proteoglycan sam-
ples (0.1 mL/well) in 20 mmol/L sodium carbonate
buffer at pH 9.5 were allowed to bind overnight to
Immulon 4 (DynaTech) microtiter immunoassay
plates. The plates were then blocked for 5 hours with
1% weight/vol BSA in 25 mmol/L TRIS HCl at pH
7.2 containing 0.15 mol/L NaCl, 0.05% vol/vol
Tween 20 and 0.02% weight/vol sodium azide
(TBS-Tween; 0.25 mL/well). The plates were
washed five times with TBS-Tween.
Anti-perlecan A76 monoclonal antibody (1
m g/mL) was added (0.1 m L/well) and allowed to
bind for 3 hours at room temperature. The plates
were washed again, and secondary antibody, a
1/1000 dilution of alkaline phosphatase–labeled
anti-mouse IgG (0.2 mL/well) was added. After 1
hour at room temperature for binding, the plates
were washed again, and a solution of Sigma 104
alkaline phosphatase substrate (1 mg/mL) in 0.1
mol/L TRIS HCl buffer at pH 9.5 was added.
Color development was allowed to proceed for up to
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12 hours at 37° C. The plates were read at A405 nm
with an automatic plate reader. A binding curve was
constructed with the perlecan standard data, and lev-
els of perlecan in the purified smooth muscle cell
media proteoglycan samples were calculated from
this calibration curve. The data were normalized on
the basis of the number of cells in culture. Assay Zap
version 2.0 software (Biosoft) was used for curve
interpolation on a Macintosh LC personal computer.
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis and immunoblotting of smooth
muscle cell media proteoglycans. Samples of
anion exchange purified smooth muscle cell media
proteoglycans were redissolved in the appropriate
buffer for particular predigestion protocols (see
later) then subjected to electrophoresis on 4% to
12% polyacrylamide gradient gels in TRIS-glycine
buffer according to the method of Laemmli.25
Samples of smooth muscle cell media proteoglycans
were predigested with keratanase (0.1 U/mg dry
weight proteoglycan) in TRIS-acetate buffer at pH
7.4 with heparitinase (10 mU/mg dry weight pro-
teoglycan) in 50 mmol/L sodium HEPES solution
at pH 7.0 containing 100 mmol/L NaCl, 1
mmol/L benzamidine, 1 mmol/L 6-amino hexa-
noic acid, 1 mmol/L ethylenediamenetetraacetic
acid (EDTA), and 2 mmol/phenylmethyl sulfenyl
fluoride for 3 hours at 37° C. Smooth muscle cell
proteoglycan samples were subjected to elec-
trophoresis at 125V for 90 minutes then elec-
troblotted to nitrocellulose and blocked overnight
in 5% weight/vol skim milk. The blots were probed
with either 1/1000 dilution 5-D-4, 1/1000 10-E-
4, 1/1000 3-G-10, 1/1000 anti-versican or 2
m g/mL A76 anti-perlecan primary antibodies. The
blots were then developed with appropriate sec-
ondary antibodies as indicated earlier and in Table I
with NBT/BCIP as substrate. Novex molecular
weight standards and affinity purified HUAEC per-
lecan (with or without heparitinase predigestion)
standards also were subjected to electrophoresis.
RESULTS
Immunofluorescence microscopic examination
readily demonstrated the presence of smooth muscle
cell a -actin in cytoskeletal elements in all of the
AAA, arterial occlusive disease, and normal smooth
muscle cell monolayer cultures, more than 99% of all
cells stained positively for the presence of smooth
muscle cell a -actin, and a hill and valley structure
typical of smooth muscle cells was evident (data not
shown).
Examination of smooth muscle cell media pro-
teoglycans by means of CAPAGE demonstrated sev-
eral proteoglycan species of differing mobilities in
this native electrophoretic system (Fig 1). Three of
these proteoglycan species had faster mobilities than
the major chondroitin sulfate–substituted and ker-
atan sulfate–substituted aggrecan populations pre-
sent in ovine articular cartilage, demonstrating that
they were of higher charge-to-mass ratios. Two of
the smooth muscle cell proteoglycan species were of
similar mobility to the dermatan sulfate–substituted
proteoglycans of articular cartilage, decorin and
Table I. Antibodies used for immunoblotting of smooth muscle cell proteoglycans
Antibody class
Clone no. and dilution used Epitope recognized Comments (eg, pretreatments required) Reference
LF-51 Rabbit polyclonal, 1/250 Human biglycan core protein Affinity purified polyclonal antibody 19, 24
raised to amino acids 11 to 24 of 
human biglycan (GVLDPDSVTPTYSA) 
conjugated to bovine serum albumin; 
therefore must block with skim milk. 
Reacts better with deglycosylated core 
protein
LF-99 Rabbit polyclonal, 1/250 Human versican core protein Affinity purified polyclonal antibody raised 24, 25
to a unique versican peptide (LHKVKV-
GKSPPVRC) conjugated to keyhole  
limpet hemocyanin
F58-10-E-4 Mouse IgM, 1/1000 N-sulfated D-glucosamine resi- Heparitinase predigestion abolished antibody 8
due of heparan sulfate reactivity
3-G-10 Mouse IgG2b 1/1000 Heparitinase generated unsatur- Requires heparitinase pretreatment; 3G10 8
ated residues on heparin sulfate epitope is not generated by the action of 
heparitinase on heparan sulfate proteoglycans 
or chondroitin sulfate lyases on chondroitin 
sulfate proteoglycans
A76 Mouse IgG1, 5m g/mL Human perlecan core protein Does not work with reduced samples 18
5-D-4 Mouse IgG, 1/5000 Corneal and skeletal keratan sulfate Does not require pretreatment 23
JOURNAL OF VASCULAR SURGERY
680 Melrose et al October 1998
biglycan. Little difference was demonstrated
between the normal and arterial occlusive disease
smooth muscle cell media proteoglycan samples in
the CAPAGE system (Fig 1). However, the fastest
migrating smooth muscle cell proteoglycan species,
which had a mobility greater than the cartilage der-
matan sulfate proteoglycans and a similar mobility to
the 36-kd chondroitin sulfate standard (Fig 1), was
largely undetectable in the AAA media samples after
day 3 in culture but was present on all days of cul-
ture in the normal and arterial occlusive disease sam-
ples (Fig 1). This species represented a mixture of
free glycosaminoglycan chains and a proteoglycan
species of high charge-to-mass ratio, which was sub-
stituted with heparan sulfate (Fig 2, B).
Smooth muscle cell media proteoglycans were
examined by means of affinity blotting with bHA to
detect proteoglycan populations containing a
domain capable of interacting with hyaluronan (Fig
3). Correlations with immunoblotting data obtained
with an antibody to human versican core protein
were established (Fig 3). On day 3 versican expres-
sion was readily detectable by means of immuno-
blotting in the AAA samples (Fig 3) but was only
just detectable in the normal and arterial occlusive
disease samples (Fig 3). Versican expression was
detectable in all samples on day 7 but was strongest
in the AAA sample. Two species of slightly different
mobilities and hence of differing charge-to-mass
ratios were evident (Fig 3, V-1 and V-2). The nor-
mal and arterial occlusive disease smooth muscle cell
versican species detected was of the same mobility as
the least mobile AAA versican species (V-1) and was
of similar mobility to a fibroblast media proteogly-
can (versican) sample (Fig 3). Smooth muscle cell
versican detected by means of affinity and
immunoblotting after CAPAGE was of lower mobil-
ity than cartilage aggrecan, which was run as an
internal standard (Fig 3). This finding was consistent
with the known structure of versican, which is less
heavily substituted with glycosaminoglycan but con-
tains a relatively large core protein compared with
aggrecan and is of lower charge-to-mass ratio and
would be predicted to be of lower mobility in the
CAPAGE system. Immunoblotting helped confirm
the identity of the hyaluronan-binding proteogly-
cans detected with bHA as versican. Both AAA ver-
sican isoforms were detected (Fig 3).
Immunoblotting of the smooth muscle cell pro-
teoglycans with a monoclonal antibody to human
perlecan (A76) demonstrated that perlecan levels
were higher in the AAA media sample compared with
arterial occlusive disease and normal smooth muscle
cell proteoglycan samples (Fig 2, A). Densitometric
scanning indicated that perlecan levels were threefold
to sixfold higher in the AAA sample compared with
the arterial occlusive disease or normal smooth mus-
cle cell samples examined. HUAEC perlecan degly-
cosylated by means of predigestion with heparitinase
was of lower mobility in the CAPAGE system com-
pared with its native counterpart (Fig 2, A). Heparan
sulfate–substituted smooth muscle cell proteoglycan
species were identified with a monoclonal antibody
to heparan sulfate 10-E-4 (Fig 2, B). Densitometric
scanning indicated that levels of the heparan sulfate
proteoglycans were higher in the AAA compared
Fig 1. Composite agarose polyacrylamide gel electrophoresis (CAPAGE) of abdominal aortic
aneurysm (AAA), arterial occlusive disease (AOD), and normal smooth muscle cell media pro-
teoglycans from monolayer culture. An ovine articular cartilage (AC) proteoglycan sample
consisting of the chondroitin sulfate (CS)–rich and keratan sulfate–rich aggrecan populations
(Agg 1, Agg 2) and the small dermatan sulfate–substituted proteoglycans decorin and biglycan
(DS PG) was run as an internal standard. The gel was stained with toluidine blue. 
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with arterial occlusive disease or normal samples.
Two to three heparan sulfate proteoglycan species
were present in the AAA smooth muscle cell media
samples (Fig 2, B). Two of the smooth muscle cell
heparan sulfate–substituted proteoglycan species
were of similar mobility to HUAEC perlecan in the
CAPAGE system (Fig 2, A and B). Biglycan was
detected in the smooth muscle cell media samples by
means of immunoblotting (Fig 2, C). Densitometric
scanning of the blot indicated that the AAA sample
contained threefold to fourfold higher levels of bigly-
can than the arterial occlusive disease or normal sam-
ples (Fig 2, C). A keratan sulfate–substituted proteo-
glycan species also present in all smooth muscle cell
media samples; however, it was present in similar lev-
els in all smooth muscle cell samples examined. This
keratan sulfate proteoglycan was of considerably
higher mobility in CAPAGE than the two aggrecan
populations of cartilage (Fig 2, D). The native form
of this keratan sulfate–substituted proteoglycan and
its free core protein were demonstrated by means of
4% to 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS PAGE) with or without ker-
atanase predigestion and immunoblotting with mon-
Fig 2. Demonstration of perlecan (A), heparan sulfate–substituted proteoglycans (B), biglycan
(C), and keratan sulfate–substituted (D) smooth muscle cell proteoglycans separated by means
of CAPAGE and identified by means of immunoblotting with monoclonal antibodies (MAb)
specific to each proteoglycan type (see Table I). Differences in proteoglycan expression levels
were quantitated by means of densitometric scanning of particular proteoglycan bands on the
blots with Scan Analysis software (Biosoft, Cambridge, United Kingdom, Ferguson, Mo). These
results are shown in the lower half of the figure below the lane of interest. Each lane was scanned
six times; the histogram represents averaged values per lane ± SD expressed in relative terms as
arbitrary absorbance units. AAA, abdominal aortic aneurysm; AOD, arterial occlusive disease;
N, normal arterial tissue; SMCs, smooth muscle cells; CS Std, chondroitin sulfate standard;
HUAEC, human umbilical artery endothelial cell; AF, annulus fibrosus; AC, articular cartilage. 
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oclonal antibody 5-D-4 (anti-keratan sulfate) to be
about 100 to 250 kd (Fig 4, A) and about 55 kd,
respectively (Fig 4, B).
Enzyme-linked immunosorbent assay (ELISA) of
media perlecan confirmed that AAA smooth muscle
cell cultures contained higher levels of perlecan than
the normal or arterial occlusive disease smooth mus-
cle cells (Fig 5). AAA smooth muscle cell cultures
contained 14.2 ± 3 ng perlecan per 1000 cells in cul-
ture on day 1. This increased to 26.3 ± 4 ng per
100,000 cells on day 7. Normal and arterial occlusive
disease media samples contained significantly lower
levels of perlecan (5.2 to 7.4 ng/100,000 cells and
5.3 to 9.7 ng/100,000 cells, respectively).
Examination of the smooth muscle cell media
proteoglycans by means of 4% to 12% SDS PAGE fol-
lowed by immunoblotting with monoclonal antibod-
ies reactive with heparan sulfate (MAb 10-E-4) and
with the unsaturated stub epitopes generated by
means of the action of heparitinase on the heparan
sulfate side chains of heparan sulfate–substituted pro-
teoglycans (MAb 3-G-10) provided information
regarding the size of the intact smooth muscle cell
heparan sulfate proteoglycan species and their core
proteins (Fig 6). The AAA smooth muscle cell media
proteoglycan samples clearly differed from the nor-
mal and arterial occlusive disease samples in terms of
the species identified with the aforementioned mon-
oclonal antibodies (Fig 6). Use of MAb 10-E-4 also
helped detect a prominent proteoglycan species of
200 to 250 kd in the AAA samples, which was not
detected with Mab A76 (Fig 6). This species possibly
represented a 250-kd heparan sulfate–substituted
basement membrane proteoglycan unrelated to per-
lecan.27,28 Use of MAb 3-G-10 helped detect two
prominent small core protein proteoglycan species of
about 38 and 45 kd in the AAA sample (Fig 6).
These also were detected with Mab A76 (Fig 6) and
thus appeared to be amino terminal fragments of per-
lecan core protein. A range of heparan sulfate–substi-
tuted proteoglycan species were evident in the AAA
samples (Fig 6). Most of these also were detected
with Mab A76 (Fig 6), suggesting that the perlecan
core protein had been extensively degraded in the
AAA monolayer cultures.
DISCUSSION
Several laboratories have demonstrated that arte-
rial smooth muscle cell subpopulations with unique
biochemical and growth properties can be cultured
in monolayers with preservation of these characteris-
tics over multiple passages.29-31 Because isolated
smooth muscle cell subpopulations do not converge
into a common phenotype in monolayer culture, it
would appear that the observed in vitro cellular
diversity is attributable to an intrinsic heterogeneity
in arterial smooth muscle cells rather than to pheno-
typic modulation of smooth muscle cells under cul-
ture conditions. An earlier study from our laborato-
ries suggested that AAA and arterial occlusive dis-
ease are quite distinct disease processes in terms of
matrix metalloproteinase expression patterns.32 It
was logical to extend these earlier observations by
using the monolayer culture system to further assess
Fig 3. Affinity and immunoblots of abdominal aortic aneurysm (AAA), arterial occlusive dis-
ease (AOD), and normal (N) smooth muscle cell media proteoglycans separated by means of
CAPAGE. The same articular cartilage (AC) proteoglycan sample as in Fig 1 was used as was
a human fibroblast media proteoglycan sample (Hum Fib PG). Arrows at left (V-1, V-2) depict
the elution positions of the two AAA smooth muscle cell versican isoforms. Arrows at right
show the elution positions of the two articular cartilage aggrecan populations.
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whether differences were evident in the phenotypic
expression of matrix components by smooth muscle
cells derived from AAA arterial occlusive disease or
normal arterial tissue.
The results obtained in this study clearly showed
that AAA smooth muscle cells produced qualitative-
ly higher levels of perlecan (and another unidentified
250-kd heparan sulfate–substituted proteoglycan),
versican, and biglycan in monolayer culture than did
normal or arterial occlusive disease smooth muscle
cells (Figs 2 through 5). This supports our earlier
contention that smooth muscle cells from AAA and
arterial occlusive disease tissues display differing
phenotypes in vitro.32 Nikkari et al.32 also demon-
strated elevated transcript levels for perlecan, synde-
can, and versican 2 to 4 weeks after injury in a rat
carotid artery balloon injury model.
This study also showed that versican synthesized
by smooth muscle cell monolayers is capable of inter-
acting with hyaluronan by means of affinity blotting.
This is the first such study to use this technique22 to
demonstrate that smooth muscle cells synthesize
aggregatable versican in monolayer culture (Fig 3).
Two versican isoforms were synthesized by the AAA
smooth muscle cells and were identified by means of
immunoblotting (Fig 3). These may represent versi-
can isoforms of differing glycosylation patterns or
proteolytically processed forms.
CAPAGE is a system extensively used for analysis
of aggrecan species in normal and diseased cartilagi-
nous tissues.22 In this study we have applied the
CAPAGE system for analysis of the large smooth
muscle cell proteoglycans perlecan and versican.
This technique offers some advantages over conven-
tional SDS PAGE for analysis of proteoglycans with
extremely large core proteins (such as versican and
perlecan) or extensive hydrodynamic domains
resulting from extensive glycosaminoglycan substi-
tution patterns. To the best of our knowledge this is
the first time this separation technique has been
applied to the analysis of versican and perlecan.
Cell-associated heparan sulfate proteoglycans
such as the syndecan family and perlecan interact
with growth factors such as FGF-2, vascular endothe-
lial cell growth factor, and epidermal growth fac-
tor.34-36 This interaction between heparan sulfate
Fig 4. Demonstration of native (A) and deglycosylated (B) free core protein of a keratan sul-
fate proteoglycan synthesized by smooth muscle cells in culture. Anion exchange–purified
media proteoglycans (30 m g/lane) were subjected to electrophoresis on 4% to 12% PAGE gels.
A, Gel was electroblotted to nitrocellulose, and the native keratan sulfate-proteoglycan was
identified by means of immunoblotting with monoclonal antibody 5-D-4 (anti-keratan sul-
fate). B, Gel was stained directly for protein with Coomassie R250 to identify the free core
protein of the keratan sulfate proteoglycan (approximately 55 kd). +, Sample predigested with
keratanase, which degrades the glycosaminoglycan component of the proteoglycan. –, Sample
not predigested.
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and a respective growth factor is essential for expres-
sion of its biologic activity. Thus FGF-2 must first
bind to heparan sulfate on the cell surface before it
can bind to tyrosine-kinase-FGF receptors that elicit
the FGF-2 response on target cells.35 Induction of
smooth muscle cell surface heparan sulfate proteo-
glycans can therefore trigger cellular behavior such as
proliferation and migration caused by the ability of
the heparan sulfate proteoglycans to bind and thus
augment the action of heparin-binding growth fac-
tors such as FGF-2, heparin-binding epidermal
growth factor, and platelet-derived growth factor. An
earlier study from our laboratory demonstrated that
smooth muscle cells from medial AAA tissue has
greater proliferative capacity in outgrowth cultures
than smooth muscle cells of normal or arterial occlu-
sive disease tissues.37 The results of this study, which
demonstrated an elevation in synthesis of heparan
sulfate proteoglycans by AAA smooth muscle cells in
culture, therefore are consistent with this interpreta-
tion. Moreover, our laboratory and others have
shown that AAA cells secrete significantly higher lev-
els of matrix metalloproteinase-2 and matrix metallo-
proteinase-9 than smooth muscle cells from normal
or arterial occlusive disease specimens.38-42 Halpert
et al.43 showed that matrix metalloproteinases secret-
ed by macrophages were localized to areas of versican
deposition in atherosclerotic lesions. This finding
suggested that the versican was acting as an in situ
substrate for matrix metalloproteinases.
The AAA smooth muscle cell cultures in this study
expressed elevated levels of versican (Fig 3), this was
present as two forms of differing charge-to-mass
ratios, which may have arisen from endogenous cleav-
age of versican core protein. Fragments of perlecan
also were identified in AAA cultures (Fig 6). Two
small D -heparan sulfate–substituted perlecan core pro-
tein fragments were prominent in the AAA cultures
and were both detected with Mab A76 and Mab 3-G-
10 (Fig 6). These fragments must have arisen from
the amino terminus of the perlecan core protein,
unlike carboxyl terminal V-8 protease resistant per-
lecan core protein fragments, which also have been
described.44 This suggests that an A76 binding epi-
tope is present within the amino terminal heparan sul-
fate–substituted region of the perlecan core protein. 
The presence of multiple core protein species in
the AAA smooth muscle cell media samples indicates
endogenous proteolysis of matrix proteoglycans
such as perlecan and versican in the monolayer cul-
tures. Such a proposal is appealing, because proteol-
ysis of smooth muscle cell heparan sulfate proteogly-
cans in situ might result in localized release of a
range of mitogenic growth factors capable of influ-
encing synthesis of the matrix metalloproteinases
and their endogenous inhibitory proteins.18,45 Such
a process might account for both the greater prolif-
erative capacity and the elevated matrix metallopro-
teinase expression displayed by AAA smooth muscle
cells in vitro.
In summary, this study demonstrated a differen-
tial relationship between proteoglycan species syn-
thesized by smooth muscle cells from AAA, arterial
occlusive disease, and normal medial vessel tissues. In
general, the levels of perlecan, versican, and biglycan
synthesized by AAA smooth muscle cells in mono-
layer culture were significantly higher than synthe-
Fig 5. Enzyme-linked immunosorbent assay of perlecan
levels in media samples from monolayer culture of smooth
muscle cells. The number of smooth muscle cells in culture
at each time point was determined by means of detaching
cells from monolayers with trypsin/EDTA and counting
the cells with a hemocytometer. Perlecan levels (inset) were
quantified relative to a binding curve constructed with
affinity-purified HUAEC perlecan and A76 monoclonal
mouse anti-human perlecan core protein. Each time point
represents a mean value calculated from six replicate sam-
ples of the smooth muscle cell cultures. Bars indicate stan-
dard deviation. The ELISA standard curve was construct-
ed from triplicate replicates of each dilution of perlecan
standard. Assay Zap software (Biosoft) was used for calcu-
lation of results from this standard curve.
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sized by the other smooth muscle cells. To what
extent this cellular behavior contributes to AAA
development in vivo awaits experimental verification.
We acknowledge the kind gifts of antibodies from Dr
L. Fisher, NIDR, NIH, Bethesda, Md.
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